Bacopa

Evidence Fact Sheet

Bacopa monnieri / Brahmi

Bacopa monnieri (Brahmi) is an Ayurvedic botanical standardized to bacoside triterpenoid saponins, studied mainly for memory and cognitive-test performance over 8-12 weeks at ~300 mg/day. Evidence is strongest for memory free recall; effects are slow-onset and inconsistent across other domains. A US DSHEA supplement; no authorized EFSA health claim.

Also known as: Bacopa monnieri · Brahmi · Bacosides A & B · Bacoside A3 · BacoMind · CDRI 08 · KeenMind · Synapsa · Bacumen

Overview

Bacopa monnieri (Brahmi) is an Ayurvedic botanical standardized to bacoside triterpenoid saponins (commonly bacosides ≥45% in branded extracts such as BacoMind, CDRI 08/KeenMind, and Synapsa). Proposed mechanisms — acetylcholinesterase inhibition, monoamine modulation, antioxidant bacoside activity, and BDNF/synaptic neurotrophic signaling — are largely preclinical and not established as clinical cognition drivers in humans. The most-validated research regimen is roughly 300 mg/day of a standardized extract for 8-12 weeks for cognitive and stress endpoints, with acute multitasking studies using single 320-640 mg doses; cognitive effects are slow-onset rather than acute. In-vitro inhibition of CYP1A2/CYP3A4 and an animal thyroid (T4) signal underlie drug-interaction caveats. Regulatory status: a US DSHEA dietary supplement (structure/function claims only, disease claims prohibited); no authorized EFSA health claim (botanical cognitive claims remain on the EFSA on-hold list); pending pathways in China and Brazil. Educational reference only, not a dosing recommendation or disease-treatment claim.

Mechanism of Action

Acetylcholinesterase (AChE) inhibition enhancing cholinergic transmission (preclinical mechanism; not demonstrated as a clinical cognition driver in humans) · Monoamine / neurotransmitter modulation (proposed up-regulation of 5-HT, dopamine and GABA tone in preclinical models) · Antioxidant free-radical scavenging by bacoside triterpenoid saponins (SOD/CAT/GPx up-regulation in animal models; limited direct human evidence) · Dendritic arborization / synaptic and BDNF-pathway neurotrophic signaling (preclinical) · NF-kB inhibition with reduced TNF-alpha / IL-6 (preclinical anti-inflammatory mechanism, not a validated human anti-inflammatory claim)

Body systems: Neurological & Cognitive · Mood & Stress Response · Immune System

Evidence-Based Benefits

Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Bacopa is not characterized as a treatment for any disease.

Cognition / Speed of Attention (Meta-Analysis)

Meta-analysis supported

9 RCTs · 518 subjectspooled trials · participants
−17.9 msTrail B · p<0.001
10.6 mschoice reaction time · p<0.001

A meta-analysis of 9 randomized controlled trials (518 subjects) found that standardized Bacopa monnieri extract significantly shortened performance on timed attention tasks versus placebo, with the authors concluding it has potential to improve cognition particularly the speed of attention. The authors cautioned that a large head-to-head trial against an existing medication would be needed for definitive efficacy.

Reported effect: shortened Trail B test (−17.9 ms; 95% CI −24.6 to −11.2; p<0.001) and decreased choice reaction time (10.6 ms; 95% CI −12.1 to −9.2; p<0.001); 9 RCTs, 518 subjects

“shortened Trail B test (-17.9 ms; 95% CI -24.6 to -11.2; p<0.001); decreased choice reaction time (10.6 ms; 95% CI -12.1 to -9.2; p<0.001); has the potential to improve cognition, particularly speed of attention”

Source: PMID 24252493 · Kongkeaw 2014 · J Ethnopharmacol

Memory Free Recall (Systematic Review)

Meta-analysis supported

9 of 17free-recall tests improved

A systematic review of 6 randomized controlled trials reported that Bacopa improved performance on 9 of 17 tests in the domain of memory free recall, with little evidence of enhancement in any other cognitive domain. This is an honest mixed signal: the memory-recall benefit is the most consistent finding, while attention and other domains showed minimal improvement, which the authors attributed partly to inconsistent measures across studies.

Reported effect: Bacopa improved performance on 9 of 17 tests in the domain of memory free recall; little evidence of enhancement in any other cognitive domains

“Bacopa improved performance on 9 of 17 tests in the domain of memory free recall... There was little evidence of enhancement in any other cognitive domains... some evidence to suggest that Bacopa improves memory free recall with evidence for enhancement in other cognitive abilities currently lacking”

Source: PMID 22747190 · Pase 2012 · J Altern Complement Med

Retention of New Information (RCT) — Partial/Null

Null / no benefit RCT supported

no changelearning rate · attention

In a 3-month double-blind RCT in 76 adults aged 40-65, Brahmi produced a significant effect on retention of newly learned information, suggesting it decreased the rate of forgetting; however the rate of learning itself was unaffected. Tasks measuring attention, verbal and visual short-term memory, retrieval of pre-existing knowledge, everyday memory, and anxiety showed no change — an honest demonstration that the benefit is narrow.

Reported effect: significant effect on retention of new information; rate of learning unaffected; no change in attention, short-term memory, retrieval, everyday memory or anxiety

“a significant effect of the Brahmi on a test for the retention of new information... the rate of learning was unaffected, suggesting that Brahmi decreases the rate of forgetting of newly acquired information... tasks assessing attention, verbal and visual short-term memory and the retrieval of pre-experimental knowledge were unaffected”

Source: PMID 12093601 · Roodenrys 2002 · Neuropsychopharmacology

Cognition, Mood & Anxiety in Older Adults (RCT)

RCT supported

In a 12-week double-blind RCT of 300 mg/day standardized extract in 48 elderly completers (mean age ~73.5), the Bacopa group improved on AVLT delayed word recall (p=0.03) and on a Stroop attention task (p=0.003) versus an unchanged placebo group. Depression (CESD-10, p=0.05), combined STAI anxiety scores, and heart rate also decreased over time for Bacopa but rose for placebo, supporting a research-context mood/stress signal alongside cognition.

Effect size: not quantified on this page — see the linked study below for the reported figures.

Source: PMID 18611150 · Calabrese 2008 · J Altern Complement Med

Safety / Tolerability (Phase I)

RCT supported

23 volunteers300→450 mg · 15+15 days

A Phase I dose-escalation safety trial gave 23 healthy adults 300 mg/day for 15 days then 450 mg/day for 15 days. Clinical, hematological, biochemical and ECG parameters showed no untoward effects; only mild, self-limiting gastrointestinal adverse events were observed, consistent with the GI tolerability profile noted in the safety summary.

Reported effect: 23 healthy volunteers, 300 mg/day x15 days then 450 mg/day x15 days; no untoward clinical/hematological/biochemical/ECG effects; mild GI adverse events that subsided spontaneously

“Detailed examination of clinical, hematological, biochemical and electrocardiographic parameters done in pre and post-treatment periods did not indicate any untoward effects... mild adverse events related to gastrointestinal system were observed in the trial, which subsided spontaneously”

Source: PMID 17442556 · Pravina 2007 · Phytomedicine

Dosage (research context · not a recommendation)

300 mg/day standardized extract (bacosides >=45%, e.g. BacoMind/CDRI 08/Synapsa) for 8-12 weeks is the most-validated cognitive/stress regimen; acute multitasking studies tested 320-640 mg single doses; DSLD market median 300 mg (range 250-700 mg). Educational reference, not a dosing recommendation. Cognition is slow-onset — most RCTs show effects only at 8-12 weeks.

Regulatory Status · 4 Markets

US · FDA: DSHEA dietary supplement (marketed under NDI / self-determined dietary-ingredient status; no independent FDA GRAS no-questions letter — GRN 0); standardized branded extracts (Synapsa/PS-BM, BacoMind, CDRI 08/KeenMind, Bacumen) sold legally. Structure/function claims only with mandatory FDA disclaimer; disease claims (Alzheimer/dementia/ADHD/epilepsy treatment) prohibited.
EU · EFSA: No authorized EFSA health claim for Bacopa monnieri — its botanical Art.13 cognitive/memory claims remain on the EFSA on-hold list (pending, never finalised), not formally absent. Sold via the Traditional Herbal Medicine / Traditional Herbal Registration (THR) route in member states under traditional-use claims only; member-state rules differ.
CN · China: Not approved in China: absent from medicine-food homology, novel-food, and SAMR health-food raw-material catalogues; no clear ingredient pathway; domestic market is cross-border e-commerce only with no functional claims.
BR · ANVISA: Registrable under RDC 243/2018 as fitoterapico (herbal medicine) or food supplement, requiring submitted safety and efficacy data; approval pathway is comparatively complex, especially for standardized-extract quality control. No Anexo V alegacao funcional for Bacopa.

Safety

Generally well tolerated in RCTs up to ~12 weeks; Phase I safety study (BacoMind 300 mg/day x 30 days, PMID 17442556) confirmed good tolerability. Most common adverse effects are gastrointestinal (nausea, cramping, increased stool frequency/diarrhea, ~10-15%) — taking with food is reported to reduce GI upset. Thyroid signal: animal data show up-regulation of T4, so caution / clinician consultation advised in hyperthyroidism. Drug-interaction signal: in-vitro inhibition of CYP1A2 and CYP3A4 (PMID 24566323) — caution with drugs metabolized by these enzymes and with sedative / anxiolytic / antidepressant co-medication. Pediatric (ADHD) evidence is very limited (single small RCT, n=31) and not a basis for marketing to children. No adequate pregnancy / lactation data.

Goals: cognitive-support

Lifestyles: high-stress

References

PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.

PMID 24252493 · Kongkeaw 2014 · J Ethnopharmacol — Cognition / Speed of Attention (Meta-Analysis)
PMID 22747190 · Pase 2012 · J Altern Complement Med — Memory Free Recall (Systematic Review)
PMID 12093601 · Roodenrys 2002 · Neuropsychopharmacology — Retention of New Information (RCT) — Partial/Null
PMID 18611150 · Calabrese 2008 · J Altern Complement Med — Cognition, Mood & Anxiety in Older Adults (RCT)
PMID 17442556 · Pravina 2007 · Phytomedicine — Safety / Tolerability (Phase I)

Frequently Asked Questions

1. What does the strongest evidence actually show for Bacopa?

The most consistent research finding is for memory free recall. A systematic review of 6 RCTs (Pase 2012, PMID 22747190) found Bacopa improved 9 of 17 free-recall tests with little enhancement in other domains, and a meta-analysis of 9 RCTs in 518 subjects (Kongkeaw 2014, PMID 24252493) found improved timed-attention performance (Trail B −17.9 ms; choice reaction time 10.6 ms, both p<0.001). These are research-context cognitive-test endpoints in studied populations, not a disease-treatment claim.

2. How fast does it work, and at what dose was it studied?

Bacopa's cognitive effects appear slow-onset rather than acute. The most-validated research regimen is around 300 mg/day of a standardized extract for 8-12 weeks; for example the Calabrese 2008 RCT (PMID 18611150) used 300 mg/day for 12 weeks. This is an educational summary of doses used in trials, not a dosing recommendation.

3. Are there honest negative findings?

Yes. In Roodenrys 2002 (PMID 12093601), a 3-month RCT in 76 adults, Brahmi improved retention of new information but did not change the rate of learning, attention, short-term memory, retrieval of prior knowledge, everyday memory, or anxiety. The Pase 2012 review (PMID 22747190) similarly found little evidence of benefit outside memory free recall — so the cognitive signal is real but narrow.

4. Is it well tolerated, and any interaction cautions?

In a Phase I trial (Pravina 2007, PMID 17442556) of 23 volunteers taking 300 mg then 450 mg/day, clinical, lab and ECG parameters showed no untoward effects, with only mild self-limiting gastrointestinal events. Separate caveats noted in the safety summary include in-vitro CYP1A2/CYP3A4 inhibition and an animal thyroid (T4) signal, so drug-interaction caution is warranted; this is evidence reporting, not clinical guidance.

Last evidence review: 2026-06-13

← Evidence library